Literature DB >> 28671049

Clinicopathological significance of c-MYC in esophageal squamous cell carcinoma.

Yu Lian1, Xiangdong Niu2, Hui Cai3, Xiaojun Yang3, Haizhong Ma3, Shixun Ma3, Yupeng Zhang4, Yifeng Chen4.   

Abstract

Esophageal squamous cell carcinoma is one of the most common malignant tumors. The oncogene c-MYC is thought to be important in the initiation, promotion, and therapy resistance of cancer. In this study, we aim to investigate the clinicopathologic roles of c-MYC in esophageal squamous cell carcinoma tissue. This study is aimed at discovering and analyzing c-MYC expression in a series of human esophageal tissues. A total of 95 esophageal squamous cell carcinoma samples were analyzed by the western blotting and immunohistochemistry techniques. Then, correlation of c-MYC expression with clinicopathological features of esophageal squamous cell carcinoma patients was statistically analyzed. In most esophageal squamous cell carcinoma cases, the c-MYC expression was positive in tumor tissues. The positive rate of c-MYC expression in tumor tissues was 61.05%, obviously higher than the adjacent normal tissues (8.42%, 8/92) and atypical hyperplasia tissues (19.75%, 16/95). There was a statistical difference among adjacent normal tissues, atypical hyperplasia tissues, and tumor tissues. Overexpression of the c-MYC was detected in 61.05% (58/95) esophageal squamous cell carcinomas, which was significantly correlated with the degree of differentiation (p = 0.004). The positive rate of c-MYC expression was 40.0% in well-differentiated esophageal tissues, with a significantly statistical difference (p = 0.004). The positive rate of c-MYC was 41.5% in T1 + T2 esophageal tissues and 74.1% in T3 + T4 esophageal tissues, with a significantly statistical difference (p = 0.001). The positive rate of c-MYC was 45.0% in I + II esophageal tissues and 72.2% in III + IV esophageal tissues, with a significantly statistical difference (p = 0.011). The c-MYC expression strongly correlated with clinical staging (p = 0.011), differentiation degree (p = 0.004), lymph node metastasis (p = 0.003), and invasion depth (p = 0.001) of patients with esophageal squamous cell carcinoma. The c-MYC was differentially expressed in a series of human esophageal tissues, and the aberrant c-MYC expression could be a potential factor in carcinogenesis and progression of esophageal squamous cell carcinoma. There was a statistical signification for c-MYC in esophageal squamous cell carcinoma patients to analyze clinicopathological features. It possibly becomes a new diagnostic indicator of esophageal squamous cell carcinoma.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; Western blot; c-MYC; clinicopathology; immunohistochemistry

Mesh:

Substances:

Year:  2017        PMID: 28671049     DOI: 10.1177/1010428317715804

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  9 in total

1.  Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.

Authors:  Ran Wei; Limin Mao; Ping Xu; Xinghai Zheng; Robert M Hackman; Gerardo G Mackenzie; Yuefei Wang
Journal:  Food Funct       Date:  2018-11-14       Impact factor: 5.396

Review 2.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

3.  C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.

Authors:  Ming-Qiang Liang; Feng-Qiang Yu; Chun Chen
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

4.  Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis.

Authors:  Yi-Hang Yuan; Jian Zhou; Yan Zhang; Meng-Dan Xu; Jing Wu; Wei Li; Meng-Yao Wu; Dao-Ming Li
Journal:  Oncol Lett       Date:  2019-06-06       Impact factor: 2.967

5.  HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma.

Authors:  Liuliu Guan; Qingqing Zou; Qian Liu; Yiguang Lin; Size Chen
Journal:  Onco Targets Ther       Date:  2020-04-08       Impact factor: 4.147

6.  Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.

Authors:  Amira Emad Elwy; Tarek Mohamed Elsaba; Ahmed Refaat Abd Elzaher; Mahmoud Ismail Nassar
Journal:  Asian Pac J Cancer Prev       Date:  2019-12-01

7.  Silencing of Peroxiredoxin 1 Inhibits the Proliferation of Esophageal Cancer Cells and Promotes Apoptosis by Inhibiting the Activity of the PI3K/AKT Pathway.

Authors:  Yingjian Song; Huimin Liu; Chunling Cui; Xiaonu Peng; Chaoyang Wang; Xudong Tian; Wenjun Li
Journal:  Cancer Manag Res       Date:  2019-12-30       Impact factor: 3.989

8.  Rehabilitation Nursing Intervention Can Improve Dysphagia and Quality of Life of Patients Undergoing Radiotherapy for Esophageal Cancer.

Authors:  Xiange Zeng; Ling Li; Wenjing Wang; Lihui Zhu
Journal:  J Oncol       Date:  2021-08-05       Impact factor: 4.375

9.  Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.

Authors:  Shahida Tasneem; Muhammad Tahir Sarwar; Muhammad Rizwan Bashir; Hamid Hussain; Jawad Ahmed; Shahid Pervez
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.